Logo do repositório
 
Publicação

Applying next-generation sequencing to track HIV-1 drug resistance mutations circulating in Portugal

2024-04Contributo em revista Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorPimentel, Victor
dc.contributor.authorPingarilho, Marta
dc.contributor.authorSebastião, Cruz S.
dc.contributor.authorMiranda, Mafalda
dc.contributor.authorGonçalves, Fátima
dc.contributor.authorCabanas, Joaquim
dc.contributor.authorCosta, Inês
dc.contributor.authorDiogo, Isabel
dc.contributor.authorFernandes, Sandra
dc.contributor.authorCosta, Olga
dc.contributor.authorCorte-Real, Rita
dc.contributor.authorMartins, M. Rosário O.
dc.contributor.authorSeabra, Sofia G.
dc.contributor.authorAbecasis, Ana B.
dc.contributor.authorGomes, Perpétua
dc.date.accessioned2026-03-19T11:38:26Z
dc.date.available2026-03-19T11:38:26Z
dc.date.issued2024-04
dc.description.abstractBackground: The global scale-up of antiretroviral treatment (ART) offers significant health benefits by suppressing HIV-1 replication and increasing CD4 cell counts. However, incomplete viral suppression poses a potential threat for the emergence of drug resistance mutations (DRMs), limiting ART options, and increasing HIV transmission. Objective: We investigated the patterns of transmitted drug resistance (TDR) and acquired drug resistance (ADR) among HIV-1 patients in Portugal. Methods: Data were obtained from 1050 HIV-1 patient samples submitted for HIV drug resistance (HIVDR) testing from January 2022 to June 2023. Evaluation of DRM affecting viral susceptibility to nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) was performed using an NGS technology, the Vela Diagnostics Sentosa SQ HIV-1 Genotyping Assay. Results: About 71% of patients were ART naïve and 29% were experienced. Overall, 20% presented with any DRM. The prevalence of TDR and ADR was 12.6% and 41.1%, respectively. M184V, T215S, and M41L mutations for NRTI, K103N for NNRTI, and M46I/L for PIs were frequent in naïve and treated patients. E138K and R263K mutations against INSTIs were more frequent in naïve than treated patients. TDR and ADR to INSTIs were 0.3% and 7%, respectively. Patients aged 50 or over (OR: 1.81, p = 0.015), originating from Portuguese-speaking African countries (PALOPs) (OR: 1.55, p = 0.050), HIV-1 subtype G (OR: 1.78, p = 0.010), and with CD4 < 200 cells/mm3 (OR: 1.70, p = 0.043) were more likely to present with DRMs, while the males (OR: 0.63, p = 0.003) with a viral load between 4.1 to 5.0 Log10 (OR: 0.55, p = 0.003) or greater than 5.0 Log10 (OR: 0.52, p < 0.001), had lower chances of presenting with DRMs. Conclusions: We present the first evidence on TDR and ADR to INSTI regimens in followed up patients presenting for healthcare in Portugal. We observed low levels of TDR to INSTIs among ART-naïve and moderate levels in ART-exposed patients. Regimens containing PIs could be an alternative second line in patients with intermediate or high-level drug resistance, especially against second-generation INSTIs (dolutegravir, bictegravir, and cabotegravir).eng
dc.identifier.citationPimentel V, Pingarilho M, Sebastião CS, Miranda M, Gonçalves F, Cabanas J, Costa I, Diogo I, Fernandes S, Costa O, et al. Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal. Viruses. 2024; 16(4):622. https://doi.org/10.3390/v16040622
dc.identifier.doi10.3390/v16040622
dc.identifier.issn1999-4915
dc.identifier.urihttp://hdl.handle.net/10400.26/62303
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.relation.hasversionhttps://doi.org/10.3390/v16040622
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHIV-1
dc.subjectdrug resistance
dc.subjectINSTIs
dc.subjectNGS
dc.subjectPortugal
dc.subjectEurope
dc.titleApplying next-generation sequencing to track HIV-1 drug resistance mutations circulating in Portugaleng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue4
oaire.citation.startPage622
oaire.citation.titleViruses
oaire.citation.volume16
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Artigo_PGomes_2024_01.pdf
Tamanho:
1.79 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

EM - Artigos Científicos